In the lat­est big in­vest­ment in gene ther­a­py man­u­fac­tur­ing, Bio­gen com­mits $200M to a ma­jor new fa­cil­i­ty in NC

You’d be for­giv­en for think­ing that the on­ly R&D ef­fort of any con­se­quence at Bio­gen be­longs to ad­u­canum­ab, its con­tro­ver­sial Alzheimer’s drug. But be­hind the up­roar around that drug, the big biotech has a full scale pipeline in play that in­cludes a grow­ing fo­cus on de­vel­op­ing gene ther­a­pies.

Now Bio­gen plans to build up the kind of man­u­fac­tur­ing mus­cle that will give it an ad­van­tage in gain­ing FDA ap­provals — where CMC is al­ways key — and then mar­ket­ing them around the world.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.